ArticleExperimental and therapeutic medicine2017
Role of microRNAs in cardiac development and disease.
Article in Experimental and therapeutic medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 57 citations in OpenAlex.
- Effect of EPOC on Serum MicroRNA Expression in Patients with Hypertension.Journal of healthcare engineering · 2022Trial
- MicroRNAs as novel biomarkers for the diagnosis and treatment of pediatric diseases.Clinical and experimental pediatrics · 2024Article
- MicroRNAs in chronic pediatric diseases (Review).Experimental and therapeutic medicine · 2024Review
- Review
- The Cardiovascular Disease (CVD) Risk Continuum from Prenatal Life to Adulthood: A Literature Review.International journal of environmental research and public health · 2022Review
- Potential impact ofMolecular medicine reports · 2022Article
- MicroRNAs in extracellular vesicles: Sorting mechanisms, diagnostic value, isolation, and detection technology.Frontiers in bioengineering and biotechnology · 2022Review
- Association between single-nucleotide polymorphisms ofOpen life sciences · 2022Article
- Linc8986 and linc0597 in plasma are novel biomarkers for systemic lupus erythematosus.Experimental and therapeutic medicine · 2021Article
- Broadly active zinc finger protein-guided transcriptional activation of HIV-1.Molecular therapy. Methods & clinical development · 2021Article
- Article
- Circulating microRNAs fluctuations in exercise-induced cardiac remodeling: A systematic review.American journal of translational research · 2021Review
- Potential Roles of MyomiRs in Cardiac Development and Related Diseases.Current cardiology reviews · 2021Review
- Dysregulated micro-RNAs and long noncoding RNAs in cardiac development and pediatric heart failure.American journal of physiology. Heart and circulatory physiology · 2020Review
- The impacts of intrauterine Bisphenol A exposure on pregnancy and expression of miRNAs related to heart development and diseases in animal model.Scientific reports · 2020Article
- MicroRNA-Mediated Direct Reprogramming of Human Adult Fibroblasts Toward Cardiac Phenotype.Frontiers in bioengineering and biotechnology · 2020Article
- LncRNA nuclear-enriched abundant transcript 1 regulates hypoxia-evoked apoptosis and autophagy via mediation of microRNA-181b.Molecular and cellular biochemistry · 2020Article
- Differential expression of novel MicroRNAs from developing fetal heart of Gallus gallus domesticus implies a role in cardiac development.Molecular and cellular biochemistry · 2019Article
- Potential Impact of MicroRNA Gene Polymorphisms in the Pathogenesis of Diabetes and Atherosclerotic Cardiovascular Disease.Journal of personalized medicine · 2019Review
- MicroRNAs in Cardiac Hypertrophy.International journal of molecular sciences · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart disease-related deaths are the highest in most societies and congenital heart diseases account for approximately 40% of prenatal deaths and over 20% of mortality in the first few months after birth. Congenital heart disease affects approximately 1% of all newborns and is the causative factor for more deaths within the first year of life as compared to all other genetic defects. Advances in treatment approaches increased life expectancy and led to an expansion of adult population with clinical manifestation of congenital heart defects in up to 90% of the children born with congenital heart diseases. Regulation of cardiac gene expression involves multiple independent enhancers that play a critical role in maintaining a restricted and specific pattern of gene expression in the heart. Cardiac transcriptional pathways are intimately regulated by microRNAs (miRNAs), which are small, regulatory RNAs, approximately 22 nucleotides in length, also coded by specific genes. These miRNAs act as suppressors of gene expression by inhibiting translation and/or promoting degradation of target protein-coding mRNAs. There are several miRNAs involved in the development of heart and dysregulation of specific miRNAs is associated with congenital and other cardiac defects. Stress responsive cardiac hypertrophy is orchestrated among other factors, by specific miRNAs. miRNAs such as miR-499 are considered useful as biomarkers of a given heart disease. Therapeutic application of miRNAs is also envisaged considering the small size and specific effects of these molecules. In this review, we addressed different roles of miRNAs in the development and diseases of the heart.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.